Blood test for liver cancer treatment response
Part of Cancer, Digestive system clinical trials.
This study looks at blood tests to see if they can predict how well liver cancer responds to a procedure called TACE. Participation involves giving blood samples and having your normal follow-up scans.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with liver cancer (hepatocellular carcinoma) confirmed by imaging or biopsy.
- You are going to receive or have received a treatment called TACE (chemoembolization), which delivers chemotherapy directly to the tumor.
- Your liver function is reasonably good (Child-Pugh score 7 or lower).
- You are fully active and able to do all your daily tasks without help (ECOG status 0).
- You will have a follow-up CT or MRI scan about 4 to 8 weeks after TACE.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking for blood markers that may help doctors learn how well TACE treatment is working for liver cancer. You need to be scheduled for TACE and have a follow-up scan to participate.
This study looks at blood and tissue samples from people with liver cancer to find markers that can predict how well treatment works and whether the cancer might come back. It may help doctors personalize treatment and follow-up care.
This study looks at whether certain blood markers can predict how well the combination of atezolizumab and bevacizumab works for people with advanced liver cancer. It aims to find out if these markers can help guide treatment decisions.
This study tests whether adding a drug (nitroglycerin) to a standard liver cancer treatment (TACE) improves the way the drug reaches the tumor. It uses imaging to see changes in blood flow, which might make the treatment more effective.
This trial tests whether measuring the liver tumor with a CT scan can help doctors plan the best treatment. It aims to improve how well the treatment works and reduce side effects.
This trial is for people with advanced liver cancer (HCC) that has spread outside the liver. It tests whether combining a TACE procedure with immunotherapy and anti-angiogenesis drugs can improve outcomes. You must not have had prior systemic therapy and must have received TACE in a specific time window around starting these drugs.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.